Kwan Cheung Keith A, Mitchell Murray D, Heussler Helen S
Centre for Children's Health Research, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia.
Centre for Clinical Trials in Rare Neurodevelopmental Disorders, Child Development Program, Children's Health Queensland, Brisbane, QLD, Australia.
Front Psychiatry. 2021 May 21;12:643442. doi: 10.3389/fpsyt.2021.643442. eCollection 2021.
Neurodevelopmental and neuropsychiatric disorders (such as autism spectrum disorder) have broad health implications for children, with no definitive cure for the vast majority of them. However, recently medicinal cannabis has been successfully trialled as a treatment to manage many of the patients' symptoms and improve quality of life. The cannabinoid cannabidiol, in particular, has been reported to be safe and well-tolerated with a plethora of anticonvulsant, anxiolytic and anti-inflammatory properties. Lately, the current consensus is that the endocannabinoid system is a crucial factor in neural development and health; research has found evidence that there are a multitude of signalling pathways involving neurotransmitters and the endocannabinoid system by which cannabinoids could potentially exert their therapeutic effects. A better understanding of the cannabinoids' mechanisms of action should lead to improved treatments for neurodevelopmental disorders.
神经发育和神经精神疾病(如自闭症谱系障碍)对儿童的健康有着广泛影响,绝大多数此类疾病尚无确切的治愈方法。然而,最近药用大麻已成功进行试验,作为一种治疗方法来控制许多患者的症状并提高生活质量。特别是大麻素大麻二酚,据报道它安全且耐受性良好,具有多种抗惊厥、抗焦虑和抗炎特性。最近,目前的共识是内源性大麻素系统是神经发育和健康的关键因素;研究发现有证据表明,存在许多涉及神经递质和内源性大麻素系统的信号通路,大麻素可能通过这些通路发挥其治疗作用。更好地理解大麻素的作用机制应该会带来针对神经发育障碍的改进治疗方法。